KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Receivables (2018 - 2025)

Moderna (MRNA) has disclosed Change in Receivables for 8 consecutive years, with -$859.0 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 28.77% to -$859.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$156.0 million through Dec 2025, up 70.79% year-over-year, with the annual reading at -$156.0 million for FY2025, 70.79% up from the prior year.
  • Change in Receivables for Q4 2025 was -$859.0 million at Moderna, down from $1.0 billion in the prior quarter.
  • The five-year high for Change in Receivables was $1.8 billion in Q1 2021, with the low at -$1.3 billion in Q4 2022.
  • Average Change in Receivables over 5 years is -$59.4 million, with a median of -$151.0 million recorded in 2023.
  • The sharpest move saw Change in Receivables surged 90850.0% in 2021, then plummeted 27100.0% in 2023.
  • Over 5 years, Change in Receivables stood at $33.0 million in 2021, then tumbled by 4069.7% to -$1.3 billion in 2022, then increased by 25.65% to -$974.0 million in 2023, then decreased by 23.82% to -$1.2 billion in 2024, then rose by 28.77% to -$859.0 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$859.0 million, $1.0 billion, and -$30.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.